Regulatory Submission Process Step by Step: The Complete 2026 Guide
Getting a drug approved is not a single event. It is a series of carefully structured regulatory interactions that span years, from the first filing that authorises human testing to the final decision that grants market access. Each step has specific documentation requirements, submission formats, review timelines, and decision points that the sponsor must navigate precisely.
Miss a step. Forget a required document. Submit the wrong version to the wrong authority. Any of these failures can add months – sometimes years – to the process.
This guide walks you through the regulatory submission process step by step, from pre-clinical stage to post-approval, covering the most important global regulatory pathways and everything you need to know to navigate them successfully in 2026.
Quick Answer
The regulatory submission process moves through five major stages: pre-clinical and IND/CTA filing (to begin human trials), clinical development (Phases I through III), pre-submission planning (Type B/pre-NDA meetings, scientific advice), marketing authorisation application (NDA, BLA, MAA submission and review), and post-approval obligations (labelling maintenance, PSURs, safety updates). Each stage requires specific, guideline-compliant documents submitted in eCTD format to the relevant regulatory authority. The entire process typically spans 10 to 15 years from discovery to first approval.
Overview: The Regulatory Submission Lifecycle
The regulatory submission journey is not a straight line – it is a series of decision gates, each requiring documented evidence that the product is safe to continue to the next stage.
The major milestones are:
- Pre-clinical research and safety testing
- Investigational New Drug (IND) or Clinical Trial Authorisation (CTA) filing
- Phase I clinical trials (safety, pharmacokinetics)
- Phase II clinical trials (proof of concept, dose finding)
- Phase III clinical trials (pivotal efficacy and safety)
- Pre-NDA/MAA meeting with regulatory authority
- NDA / BLA / MAA compilation and submission
- Regulatory review and information requests
- Approval decision and labelling negotiations
- Post-approval obligations and lifecycle management
Stage 1: Pre-Clinical Research and Regulatory Preparation
Before any drug can be tested in humans, it must be characterised pharmacologically and toxicologically in pre-clinical studies. These studies assess:
- Pharmacodynamics (how the drug works)
- Pharmacokinetics (how the body processes the drug)
- Toxicology (what adverse effects are observed at various doses)
- Genotoxicity and carcinogenicity (for longer-term exposure products)
- Manufacturing quality and formulation stability
The data from these studies forms the foundation of the first human regulatory submission. At this stage, regulatory medical writers begin producing non-clinical summary documents and toxicology reports that will appear in CTD Modules 2 and 4.
Regulatory preparation at this stage also involves selecting the correct regulatory pathway, determining the target product profile (TPP), and engaging early with regulatory authorities where possible, such as pre-IND meetings with the FDA and Scientific Advice with the EMA.
Stage 2: IND / CTA Filing – The Gateway to Human Trials
United States: Investigational New Drug (IND) Application
Before beginning Phase I clinical trials in the US, sponsors must file an Investigational New Drug (IND) application with the FDA. The FDA has 30 days to review the IND and issue a clinical hold if there are safety concerns. If no hold is issued, the trial may proceed.
IND components include:
- Cover letter and FDA Form 1571
- Investigator Brochure (IB)
- Clinical Study Protocol for the proposed Phase I trial
- Pre-clinical pharmacology and toxicology data summary
- Chemistry, Manufacturing, and Controls (CMC) information
- Previous human experience (if any)
- Investigator qualifications
IND amendments must be submitted throughout the development programme whenever protocols are modified or significant new safety information emerges.
European Union: Clinical Trial Authorisation (CTA) via EU CTIS
In the EU, clinical trials require authorisation through the Clinical Trials Information System (CTIS), which manages the process under EU CTR (Regulation 536/2014). Unlike the US IND, the EU process requires both regulatory authority approval and ethics committee approval, coordinated through CTIS for multi-member-state trials.
United Kingdom: Clinical Trial Authorisation (CTA) via MHRA
Post-Brexit, the MHRA manages its own CTA process independently of the EU. Submissions are made via the MHRA’s DMOS system. The MHRA has introduced an innovative licensing pathway for certain product types.
India: CDSCO Permission
In India, the Central Drugs Standard Control Organisation (CDSCO) requires regulatory permission before any clinical trial involving Indian patients can begin. CDSCO now accepts eCTD-formatted submissions for new drug applications.
Australia: CTA or CTN Scheme
In Australia, clinical trials operate under either the CTN (Clinical Trial Notification) or CTA (Clinical Trial Approval) scheme, administered by the TGA. Most trials use the CTN scheme, which allows trials to proceed with ethics approval and TGA notification, making Australia one of the fastest countries in which to initiate a trial.
Stage 3: Clinical Development – Phases I, II, and III
During clinical development, the sponsor submits ongoing regulatory documentation including:
- Protocol amendments – whenever the clinical protocol is modified
- IND annual reports (FDA) – annual summaries of all clinical and nonclinical progress
- DSUR (Development Safety Update Report) – annual safety summaries required under ICH E2F for most major markets
- Investigator Brochure updates – at least annually, or whenever significant new safety information is available
- Safety reporting – individual case safety reports (ICSRs) for serious adverse events submitted within required timelines (7 or 15 days depending on seriousness and expectedness)
End-of-Phase II meetings (FDA) or Scientific Advice (EMA, MHRA) are critical interactions where sponsors discuss Phase III design, endpoints, and regulatory expectations before committing to the pivotal trial. These meetings are the most valuable regulatory engagement available to sponsors.
Stage 4: Pre-Submission Planning – The Pre-NDA / Pre-MAA Phase
Once pivotal trial data is available, the submission process enters its most intensive phase. Pre-submission planning typically begins 12 to 18 months before the planned submission date.
Pre-NDA Meeting (FDA)
Sponsors request a Type B pre-NDA meeting with the FDA to align on:
- Proposed NDA content and format
- Any remaining open regulatory questions
- Labelling strategy (proposed indications, dosing, safety sections)
- Risk Evaluation and Mitigation Strategy (REMS) if required
- Planned submission timeline
Scientific Advice (EMA / MHRA)
The EMA offers pre-submission scientific advice through its Scientific Advice Working Party (SAWP). EMA scientific advice is not binding, but following it and demonstrating alignment in the submission strengthens the application’s credibility. The MHRA offers equivalent Innovation Office and Scientific Advice services.
Stage 5: Building the Marketing Authorisation Application
The Common Technical Document (CTD) Structure
All major regulatory submissions – FDA NDAs/BLAs, EMA MAAs, MHRA applications, TGA submissions – use the Common Technical Document (CTD) format, submitted electronically as an eCTD.
Module 1 – Regional Administrative Information: Content varies by country. For the FDA, it includes Form FDA 356h, cover letter, labelling in SPL format, and patent/exclusivity information. For the EMA, it includes EU qualified person information, GMP certificates, and product information in all required EU languages.
Module 2 – Summaries and Overviews: The most read module. Contains the Quality Overall Summary, Non-Clinical Overview, Clinical Overview (2.5 – integrated benefit-risk argument), and Clinical Summary (2.7 – detailed summaries of all clinical data). This is where the sponsor makes their most direct case for approval.
Module 3 – Quality (CMC): Chemistry, manufacturing, and controls – drug substance and drug product specifications, manufacturing processes, stability data.
Module 4 – Non-Clinical Study Reports: Full pharmacology, pharmacokinetics, and toxicology study reports.
Module 5 – Clinical Study Reports: All clinical study reports from Phase I through III studies. The largest module in most submissions.
eCTD Technical Requirements in 2026
- The FDA requires eCTD v3.2.2 as the minimum standard, with eCTD v4.0 now accepted and increasingly preferred
- The EMA is mandating eCTD v4.0 for new Marketing Authorisation Applications
- Japan’s PMDA requires eCTD v4.0 only from April 2026
eCTD v4.0 brings more granular document structuring, improved cross-referencing, and better support for structured data – but requires writers and publishers with specific technical expertise in the new standard.
Stage 6: Submission and Review
For FDA submissions: the NDA or BLA is submitted via the FDA’s Electronic Submissions Gateway (ESG). The FDA conducts a 60-day filing review. A Refuse to File letter – issued at day 74 – is the most costly early-stage outcome, typically caused by significant documentation gaps or technical deficiencies.
For EMA submissions: the MAA is submitted through the EMA’s CESP portal. The CHMP validates the submission and begins the 210-day review clock.
Review Timelines by Authority
Authority | Standard Review | Priority / Accelerated Review |
FDA (US) | ~10 months (PDUFA goal) | ~6 months (Priority Review) |
EMA (EU) | Up to 210 active days | 150 days (Accelerated Assessment) |
MHRA (UK) | ~150 days (standard) | Innovative Licensing and Access Pathway |
TGA (Australia) | 255 working days | 150 working days (Priority Review) |
CDSCO (India) | 12 months | 6 months (accelerated) |
During review, regulatory authorities issue questions – FDA Additional Information requests, EMA Day 120 and Day 180 lists of questions, MHRA Information Requests. Each requires a written response prepared by the regulatory medical writing team. Response quality is critical: a clear, complete, precisely targeted response can resolve an issue in one cycle; a poorly drafted one extends the review.
Stage 7: Approval and Post-Approval Obligations
FDA approval is issued as an Approval Letter with final labelling. EMA issues a positive CHMP opinion, followed by European Commission marketing authorisation (typically 67 days after the CHMP opinion). MHRA issues a marketing authorisation directly.
Before final approval, sponsors negotiate labelling – the prescribing information that accompanies the approved product. Regulatory medical writers prepare and revise labelling documents throughout this negotiation.
Post-approval obligations include:
- PSURs / PBRERs – submitted on defined schedules to the EMA, MHRA, and other authorities
- Variations and amendments – any change to the approved product requires a formal variation submission
- Annual reports (FDA) – annual summaries of safety, manufacturing, and distribution data
- Post-market surveillance studies – if required as approval conditions
- Label updates – when new safety information emerges
Frequently Asked Questions
An Investigational New Drug (IND) application is filed with the FDA before beginning clinical trials in the US. The FDA has 30 days to review it; if no clinical hold is issued, the trial may proceed. Equivalent submissions include the CTA in the EU/UK and clinical trial permission in India via CDSCO.
An NDA (New Drug Application) is filed for small molecule drugs. A BLA (Biologics License Application) is filed for biologics, including monoclonal antibodies, gene therapies, vaccines, and blood products. Both use the eCTD format and CTD structure but have different review standards and documentation requirements.
The electronic Common Technical Document (eCTD) is the standard electronic submission format used by major regulatory agencies, including the FDA, EMA, MHRA, TGA, and PMDA. In 2026, eCTD v4.0 is being adopted, requiring updated technical capabilities from sponsors and regulatory teams.
A Type B meeting is one of the most common types of FDA-sponsor interaction and includes meetings such as End-of-Phase II and pre-NDA meetings. End-of-Phase II meetings allow sponsors to align Phase III trial design and NDA plans with the FDA before investing in a pivotal trial.
A Complete Response Letter (CRL) means the FDA cannot approve the application as submitted. Sponsors must prepare a Complete Response addressing each deficiency cited by the FDA. The additional time required can vary depending on the nature and scope of the deficiencies.
The full regulatory journey from first human trials to marketing approval typically takes 10 to 15 years, although expedited pathways such as FDA Breakthrough Therapy or EMA PRIME can potentially shorten the timeline. The regulatory review phase alone, from NDA or MAA submission to a decision, can take several months depending on the applicable review pathway and agency.
Major expedited or accelerated pathways include FDA Fast Track, FDA Breakthrough Therapy Designation, FDA Priority Review, the EMA PRIME Scheme, EMA Accelerated Assessment, and the MHRA Innovative Licensing and Access Pathway (ILAP). Eligibility and review timelines vary depending on the product and regulatory criteria.
Post-approval obligations may include Periodic Safety Update Reports (PSURs/PBRERs), FDA Annual Reports, variation applications for approved changes, post-market surveillance study reports, and responses to regulatory safety queries. Regulatory obligations can continue throughout the product’s commercial lifecycle.
Conclusion
The regulatory submission process is one of the most rigorous, high-stakes document management challenges in any industry. Every stage has precise requirements, strict timelines, and consequences for getting it wrong.
Understanding the process – from IND to NDA, from eCTD filing to post-approval PSUR obligations – is essential for anyone involved in pharmaceutical development, regulatory affairs, or clinical operations.
The sponsors who navigate this process most successfully are those who plan early, engage with regulatory authorities proactively, and invest in the regulatory medical writing quality that determines whether clinical evidence translates into approval.
Leave a Reply